Protected: Diagnosis of cardiac amyloidosis

Released 5 May 2026     Expires: 05 May 2028      Programme: Cardiac amyloidosis 1 CPD/CME credit

Sponsorship Statement: This content has been developed and funded by Pfizer Ltd in collaboration with a UK Healthcare Professional.
Click here for Prescribing Information for Vyndaqel (tafamidis).

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-VYN-GBR-2999 │ May 2026

This content is password-protected. To view it, please enter the password below.

back to top